Nowicky J W, Manolakis G, Meijer D, Vatanasapt V, Brzosko W J
Ukrain Anti-Cancer Institute, Vienna, Austria.
Drugs Exp Clin Res. 1992;18 Suppl:51-4.
Thirty six stage III cancer patients were treated with Ukrain, a semisynthetic drug derived from Chelidonium majus L. alkaloids conjugated with thiophosphoric acid. The drug was injected intravenously every second day in a dose of 10 mg per injection. Each patient received 300 mg of the drug (30 injections). The cytostatic effect of Ukrain was monitored clinically and by ultrasonography (USG) and computer tomography (CT), as well as by determination of CEA and CA-125 in the sera of patients with rectal and ovarian cancers, respectively. The influence of Ukrain on immune parameters was evaluated by monoclonal antibodies (MAb) to CD2, CD4, CD8 and CD22. The influence of Ukrain on immune parameters in cancer patients was matched with its effect on these parameters in 20 healthy volunteer controls. The results obtained indicate that Ukrain, in a concentration not cytostatic in normal cells, is cytostatic for malignant ones, and may suppress the growth of cancer. The compound also has immunoregulatory properties, regulating the T lymphocyte subsets.
36名III期癌症患者接受了 Ukrain 的治疗，Ukrain 是一种半合成药物，由白屈菜生物碱与硫代磷酸结合而成。该药物每隔一天静脉注射一次，每次注射剂量为10毫克。每位患者接受300毫克药物（30次注射）。通过临床、超声检查（USG）和计算机断层扫描（CT）监测 Ukrain 的细胞抑制作用，并分别通过测定直肠癌和卵巢癌患者血清中的癌胚抗原（CEA）和糖类抗原125（CA-125）来进行监测。通过针对CD2、CD4、CD8和CD22的单克隆抗体（MAb）评估 Ukrain 对免疫参数的影响。将 Ukrain 对癌症患者免疫参数的影响与其对20名健康志愿者对照的这些参数的影响进行匹配。所得结果表明，Ukrain 在对正常细胞无细胞抑制作用的浓度下，对恶性细胞具有细胞抑制作用，并可能抑制癌症生长。该化合物还具有免疫调节特性，可调节T淋巴细胞亚群。
